Vertex Pharmaceuticals announced that Health Canada has accepted for review its New Drug Submission (NDS) for vanzacaftor/tezacaftor/deutivacaftor. This investigational therapy is a once-daily triple combination treatment for people living with cystic fibrosis (CF).
The submission targets patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This represents a potential next-in-class medicine for CF.
This regulatory acceptance marks a key step towards potentially expanding treatment options for CF patients in Canada. The vanza triple aims to further improve CFTR function and offers the convenience of once-daily dosing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.